INSIDE PHARMA goes from strength to strength
Time to move supply chain malfeasance centre stage
INSIDE PHARMA has been growing nicely
From its inception in January 2022, readership of INSIDE PHARMA has been moving from strength to strength. We are now approaching 7,000 subscribers, which has exceeded my original expectations by a country mile.
At the beginning, it was about winning paid subscribers, after the COVID scam took away my consultancy work at PharmaFlow. My last paid assignment in 2019 was to carry out a strategic review for a company renting out cold chain management containers for shipping temperature sensitive biologic products, including advanced therapies:
If you click on the link, you will see the range and complexity of shipping biologic products around the globe. Tower has grown exponentially since I helped them with consulting advice.
Paid Subscribers have been a lifeline
It took me a while, but eventually my paid subscriber base grew to a point where I had enough coming in to allow me to be less concerned about income. It’s still not a fo…